A fundamental biologic principle is that diverse biologic signals are channeled through shared signaling cascades to regulate development. Large scaffold proteins that bind multiple proteins are capable of coordinating shared signaling pathways to provide specificity to activation of key developmental genes. Although much is known about transcription factors and target genes that regulate cardiomyocyte differentiation, less is known about scaffold proteins that couple signals at the cell surface to differentiation factors in developing heart cells. Here we show that AKAP13 (a.k.a. Brx-1, AKAP-Lbc, protoLbc), a unique AKAP-GEF belonging to the Dbl-family of oncogenes, is essential for cardiac development. Cardiomyocytes of AKAP13-null mice had deficient sarcomere formation and developing hearts were thinwalled and mice died at E10.5-11.0. Disruption of AKAP13 was accompanied by reduced expression of MEF2C. Consistent with a role of AKAP13 upstream of MEF2C, AKAP13-siRNA led to a reduction in MEF2C mRNA and over expression of AKAP13 augmented MEF2C-dependent reporter activity. The results suggest that AKAP13 coordinates Gα 12 and Rho signaling to an essential transcription program in developing cardiomyocytes.
A fundamental biologic principle is that diverse biologic signals are channeled through shared signaling cascades to regulate development. Large scaffold proteins that bind multiple proteins are capable of coordinating shared signaling pathways to provide specificity to activation of key developmental genes. Although much is known about transcription factors and target genes that regulate cardiomyocyte differentiation, less is known about scaffold proteins that couple signals at the cell surface to differentiation factors in developing heart cells. Here we show that AKAP13 (a.k.a. Brx-1, AKAP-Lbc, protoLbc), a unique AKAP-GEF belonging to the Dbl-family of oncogenes, is essential for cardiac development. Cardiomyocytes of AKAP13-null mice had deficient sarcomere formation and developing hearts were thinwalled and mice died at E10.5-11.0. Disruption of AKAP13 was accompanied by reduced expression of MEF2C. Consistent with a role of AKAP13 upstream of MEF2C, AKAP13-siRNA led to a reduction in MEF2C mRNA and over expression of AKAP13 augmented MEF2C-dependent reporter activity. The results suggest that AKAP13 coordinates Gα 12 and Rho signaling to an essential transcription program in developing cardiomyocytes.
We previously reported cloning and characterization of a human 5.3kilobase (kb) brx-1 transcript that encoded a 170kDa Dbl family member (1) and later localized the gene to chromosome 15q24-25 (2) . Larger transcripts of the gene were subsequently isolated (3) and based on its AKAP region, the gene we initially called BRX is now known as AKAP13.
The central Dbl-homology (DH) or guanine nucleotide exchange region (GEF) is present in all native transcripts of AKAP13 (Fig. 1) . The lbc oncogene (4), derived from two chromosomes 15 and 7 (5), contains the GEF region of AKAP13 but lacks the Nterminus and carboxyl regions. The GEF domain of AKAP13 was shown to bind RhoA and activate Rho-family GTPases (3, 5, 6) . Rho GTPases have been reported to influence the cell cytoskeleton and sarcomere development in cardiomyocytes (7) (8) (9) . RhoA, a target of AKAP13, influences at least 11 downstream effectors (10) , including two factors essential for cardiomyocyte differentiation, serum response factor (SRF) and GATA-4 (8, 11, 12) . AKAP13 was also shown to play a role in cardiac hypertrophy (13) via myocyte enhancer factor-2 (MEF2). Despite the established role for RhoA in cardiac development, the importance of AKAP13 in the developing heart has not been described.
Function of the carboxyl region of proteins encoded by AKAP13 has remained enigmatic. The carboxyl region of the brx-1 transcript encoded a LXXLL nuclear receptorinteracting domain (NRID), and BRX-1 protein was found to specifically interact with nuclear hormone receptors (1, 14, 15) . Homodimerization of the carboxyl region has been reported to regulate Rho-GEF activity of the protein (16) . These observations suggest the carboxyl region of AKAP13 functions to regulate GEF activity and couple protein kinase A and Rho-GEF activity to downstream effectors.
AKAP13 is differentially spliced and encodes several modular proteins of varying length in the N-terminal region that comprises the protein kinase A anchoring motif (Fig. 1) . The brx-1 transcript (1) encodes the smallest naturally occurring protein of AKAP13, owing to an abbreviated AKAP domain (3) . AKAP13 proteins have been shown to coordinate signals originating from the cell membrane including thrombin (17) , LPA receptors (3, 15) , and the osmoreceptor (18) . Specifically, AKAP13 proteins have been shown to interact with Gα 12 (3, 17) , Gα 13 (19), Gα 14 (20) , Gq (19, 20, 21) and possibly Gα 15 (15) .
Despite considerable evidence suggesting the importance of AKAP13 in vitro, the in vivo role of the protein has remained unclear. To assess the in vivo physiologic role of BRX-1 (AKAP13) we pursued a targeted loss of function approach. Here we report that loss of function of AKAP13 in the mouse resulted in a thin myocardium and an embryonic lethal phenotype. We show that AKAP13 is required for cardiac development and induction of normal levels of MEF2C during cardiomyocyte differentiation.
Experimental Procedures
Nomenclature-AKAP13 is the gene that encodes the brx-1 transcript of 5.3 kilobases that encodes BRX (1), and a larger transcript of 10.0 kilobases that encodes the protein AKAP13 (also known AKAP-BRX or AKAP-LBC [refs. [3] [4] [5] ). The relationship of the different transcripts is shown in Fig. 1A . Gene targeting-Murine cDNA clones were isolated from a spleen cDNA library (Stratagene, La Jolla, CA) sequenced, and cDNA regions from the carboxyl and GEF domain of murine brx were used to identify a genomic fragment containing the GEF region of mAKAP13 from a BAC library (GenomeSystems Inc., St. Louis, MO). Overlapping genomic clones were verified by Southern analysis and DNA sequencing. The targeting vector RMV1-pPNT was constructed by insertion of a 1.6kb NotI-XhoI fragment to the 5' arm and a 5.0kb EcoRI-EcoRI (RI-RI) fragment as the 3'-arm of the murine AKAP13 gene, replacing a critical exon in the Dblhomology (DH) domain and 5.39 kb of flanking genomic sequence with the Neo r cassette. The targeting vector was sequenced, linearized with HindIII, and electroporated into 129 ES cells. The targeted event on the 5' end of the gene was confirmed by Southern blot hybridization of BamHI digested DNA and hybridization with two 5' probes ( Fig. 1) . Targeting of the 3' region was confirmed using Southern analysis of PCR products ( Fig.  S1A and S1B). Additional Southern and PCR analyses substantiated correct recombination event and excluded non-homologous events (not shown). Northern analysis of multi-tissue mRNA blot using the RI-RI fragment from the 3' region of the murine AKAP13 cDNA as described (1) . A 9.5-10.0kb band was detected in RNA harvested from heart tissues. Genotyping and embryo preparationGenotypes were analyzed using primers (5'-AAC CCA GTG TGA GCC CAA TAG TC-3') and (5'-TGC AAA GTA GAG CGG GAA AGA GA-3') for the wild-type allele; and (5'-GGG CGC CCGGTTCTT TTT-3') and (5'-CTG CCG CGC TTG TTC TCC TCTTCC'3') for the mutant allele. Reverse transcription (RT)-PCR-RT-PCR for AKAP13 mRNA in mutant embryos was performed using the Absolutely RNA kit (Stratagene) followed by the Ambion 2 step method per the manufacturer's instructions. The 5' primer for RT-PCR was (5'-CGG GAG TGT GTT TCT GAA-3'); the 3' primer was (5'-GGT CCT CCT TTG AGA GCC TC-3'). Real-time RT-PCR-Embryonic hearts were immediately snap frozen. Total RNA was isolated using RLT buffer (RNeasy) isolation method according to the manufacturer's instructions (Qiagen, Gaithersburg, MD, USA). Quantitative PCR was performed using an ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA) with duplicates of 25μl reaction mixture in Micro Amp optical 96-well reaction plates and sealed with Optical Adhesive Film (Applied Biosystems). Real-time   RT-PCR  was  conducted  with  oligonucleotide primers for mouse AKAP13,  MEF2C, and 18s as follows: AKAP13  forward, 5'-TGA GAT TTA CAC AAA GAC  AG-3'; AKAP13 reverse, 5'-TCA GTG AGT  AGA ACT GCT TG-3'; MEF2C forward, 5'-TGG ATG AGC GTA ACA GAC AG-3';  MEF2C reverse, 5'-TGA GCA ACA CCT  TAT CCA TG-3'; 18s forward, 5'-CTT AGA  GGG ACA AGT GGC G-3'; 18s Cell culture and transfection-Embryo hearts were dissected and dispersed cells were cultured in DMEM + 20% fetal bovine serum at 37°C in 5% CO 2 . All primary cultures were verified to be spontaneously contracting, or stained positively for cardiac myosin (Abcam). After 2-4 days, cells were re-plated on collagen or fibronectin (FNC coating mix, AthenaES, Baltimore, MD) coated slides (Labtek II chamber slides, Nalge Nunc Intl., Naperville, IL) for confocal studies. Transfection studies were performed as described using expression constructs for Brx and Gα 12 QL and the c-fos SRE-luciferase reporter (14) . Following overnight incubation cells were lysed, lysates normalized for protein content and luciferase assays were performed. H9C2 cells derived from embryonic heart tissue were obtained from American Tissue Type Collection (Manassas, VA). A Mef2c cDNA was amplified from skeletal muscle cDNA library (Clontech, Mountain View, CA) and subcloned into plasmid pM (Clontech) to generate pM-MEF2C. Cells for transfection were grown on collagen-coated plates. Transmission electron microscopy-Dissected embryo hearts were placed directly into Teflon baskets, fixed with glutaraldehyde and prepared for scanning electron microscopy using standard techniques. Grids were examined with a Philips CM10 electron microscope. Confocal microscopy-Primary cardiomyocyte cultures were fixed, permeabilized with 0.2% Triton-X 100, blocked using 1% BSA and 10% normal goat serum and incubated either with 4362 murine anti-Brx polyclonal antibody or monoclonal anti-Brx (Upstate) at 1:50 dilution overnight at 4 o C. For secondary antibody either FITC (anti-rabbit, 1:100) or Alexa-594 (anti-mouse, 1μg/ml; Invitrogen) was used. DAPI (Sigma-Aldrich) was added at 0.1µg/ml in PBS before the cells were examined with an Axiovert 405M epifluorescence inverted light microscope (Carl Zeiss, Oberkochen, Germany). Images were acquired with a CCD camera (Hamamatsu Orca, Shizuoka, Japan). To study filamentous actin primary cultures of cardiac cells were fixed with 4% formaldehyde. Phalloidin-FITC (Sigma-Aldrich) antibody or Alexa 546-Phalloidin (Invitrogen) was used per the manufacturer's instructions. Mouse monoclonal (BA-G5) specific for heavy chain cardiac myosin (Abcam) was used at 1:200 to detect cardiac myosin. MEF2C was detected using (E-17, Santa Cruz Biotechnology) 1:50 overnight at 4°C. Images were examined as described and intensity of staining was quantified using ImageJ analysis (Bethesda, Maryland) of 64X mag. images. Knockdown procedure-After overnight incubation of H9C2 cells, 0.45μg of the siRNA for Brx or AllStars negative control siRNA (Qiagen) were transfected with xtremeGENE siRNA (Roche). Cells were harvested 24 hours and RNA was extracted using RNeasy mini kit (Qiagen) per the manufacturer's instructions. The reverse transcription reaction was performed with random hexamers with the TaqMan reverse transcriptase kit (Applied Biosystems, Foster City, CA). The following primer pairs were used (AKAP13 forward: 5'-AGG ATC ACC AAG TAC CCA GT-3' ; Reverse : 5'-CAT CTG CCC ACT CTT CAT TC-3'); (SRF forward: 5'-GGA GTT CAT CGA CAA CAA GC-3' ; Reverse: 5'-GTA TAC ACA TGG CCT GTC TC-3'); (GATA-4 forward: 5'-TCT CAC TAT GGG CAC AGC AG-3' ; Reverse: 5'-CGA GCA GGA ATT TGA AGA GG-3'); (GAPDH forward: 5'-ATG GTG AAG GTC GGT GTG AA-3' ; Reverse: 5'-GGG TAG AGT CAT ACT GGA AC-3'). Reactions were performed in triplicate using the SYBR Green PCR Master Mix (Applied Biosystems) in an ABI PRISM 7700 SDS lightcycler (Applied Biosystems).
GST-binding studies-
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S-labeled in vitro transcribed and translated proteins were tested for binding to glutathione-S transferase (GST)-fused Brx proteins bound to GSTsepharose beads essentially as described (1) . pEXP-RXRβ and constructs expressing GSTfused full-length Brx or its C-terminal fragment (2.10) have been described (1) . Statistics-Results are reported as mean+ standard error of the mean (s.e.m.). Values were compared using an unpaired, two-tailed Student's t-test with alpha=0.05 or =0.01, and were reported as P values. Tests were performed with SAS (Cary, NC).
RESULTS
Loss of AKAP13 is associated with an
arrest of heart development. Following cloning and characterization of the human BRX-1 (1), we cloned the murine cDNA and murine BRX gene (hereafter called AKAP13). The mouse AKAP13 gene was targeted in embryonic stem cells using homologous recombination resulting in a deletion of critical residues in the GEF region of AKAP13 ( Mice heterozygous for the null AKAP13 allele appeared grossly normal but exhibited impaired glucocorticoid action (15) and an altered lymphocyte response to osmotic stress (18) . Examination of wild-type and heterozygous embryos using whole mount immunohistochemistry revealed staining for AKAP13 protein in the forebrain, limb bud, 1 st brachial arch, and developing heart (Fig. 2E) . Mice heterozygous for the null AKAP13 allele, while sub-fertile, were intercrossed with C57/BL6 mice to yield embryos homozygous for the null AKAP13 allele. Amplification of AKAP13 transcripts using RT-PCR from embryos with two null AKAP13 alleles (-/-) failed to reveal any AKAP13 transcripts (Fig.  1D [see also real-time RT-PCR results in Fig.  6A] ), indicating that the mutant gene was either not transcribed or the mutant mRNA transcript was unstable.
Genotypes of 438 offspring from 74 heterozygous crosses revealed all newborn mice to be either wild-type or heterozygous, indicating that homozygous mutation of the AKAP13 allele resulted in embryonic lethality (Table l) . Heterozygous adult mice haploinsufficient for the allele exhibited reduced mRNA and protein (18), as expected. Genotypes of embryos from timed pregnancies confirmed that embryos homozygous for the null AKAP13 allele were present at the predicted Mendelian frequency before E9.0-10.0; however, after E10.5-11.0 resorbing nidation sites were observed ( Table 2) . Dissection of AKAP13 -/-embryos revealed normal development until E8.0-8.5. Mutant -/-embryos at E9.0-9.5 were typically within 2 somite pairs of wild-type embryos (Fig. 2) , but by E10 homozygous null embryos appeared developmentally delayed compared to wildtype littermates with reduced size of the forebrain, constriction of the nuchal region, and a hypoplastic 1st brachial arch (Fig. 2F) . For this reason, experiments were performed at E9.0-9.5.
Importantly, cardiac development of homozygous embryos was abnormal as the hearts became enlarged and developed a pericardial effusion. Haematoxylin and eosin (H&E) sections of AKAP13-null embryos revealed the developing myocardium to be thinned with reduced trabeculation (Fig. 2D , K, L). The arrest of heart development after E9.0-9.5 suggested that AKAP13 was required for cardiomyocyte differentiation. Immunohistochemical analysis revealed strong staining for AKAP13 in newborn and adult hearts (Suppl. Fig. 2 ). Northern and Western blots indicated that the primary cardiac transcript size was 9.5-10.0 kilobases (Fig. 1E ) and encoded 210-220 kDa protein (Fig. S2D) . Staining of developing hearts from wild-type and heterozygous mice at E9.0-9.5 with an antisera directed against AKAP13 revealed strong staining in the myocardium (Fig. 2E,  G) . The primary ring was visible in hearts of AKAP13-null embryos (Fig. 2F, arrowhead) ; however, chamber development slowed and arrested by E9.5-10.0.
As an initial approach to examine the mechanism responsible for arrest of cardiac development we assessed markers of proliferation and apoptosis. Intensity of staining for the Ki67 proliferation antigen did not differ between wild-type and homozygous null embryos (Fig. 2 I-L) . Analysis of embryos at E9.0-9.5 using a TUNEL assay showed no increase in apoptosis in AKAP13 -/-embryos, consistent with an arrest in development, rather than an increase in programmed cell death (Fig. 2 M, N; Fig. S3 ).
AKAP13 is co-localized to actin and myosin filaments in developing cardiomyocytes. To further define the mechanism responsible for the failure of heart development we examined the subcellular localization of AKAP13 in primary cultures of cardiomyocytes from wild-type or AKAP13 -/-embryos. AKAP13 protein was localized to filaments in cardiac cells of wild-type mice. An identical pattern of staining was observed for both a monoclonal antibody (Fig. 3C ) and polyclonal anti-sera directed against different regions of AKAP13 (Fig. 3A) , confirming specificity of detection.
Of particular interest, confocal microscopic studies of doubly stained cells colocalized AKAP13 to filaments that stained positively for actin (Fig. 3D) . Co-localization of AKAP13 with the cytoskeleton had not been previously reported. We noted that most, but not all, of the AKAP13 protein was closely associated with cytoskeletal filaments. Staining intensity for AKAP13 protein in heart cells derived from AKAP13 -/-embryos ( Fig. 3I ) resembled background staining with preimmune sera (Fig. 3J) , consistent with absence of protein, as expected based on RT-PCR results (Fig. 1D) . To further explore the colocalization of AKAP13 with cytoskeletal filaments, cardiomyocytes derived from E9.5 mice were stained with a monoclonal antibody specific for cardiac myosin and anti-sera directed against AKAP13 (Fig. 3 E-H) . AKAP13 protein also co-localized to filaments that stained positively for cardiac myosin.
The co-localization of AKAP13 with actin and myosin led us to examine sarcomere development in the AKAP13-null mice because: 1) Rho GTPases have been shown to be required for normal sarcomere development in cardiomyocytes (7-9); and 2) SRF promotes actin polymerization following serum deprivation, and targeted disruption of SRF was accompanied by altered sarcomere structure (22) (23) (24) (25) . Electron micrographs of wild-type embryonic hearts at E9.0-9.5 showed normal sarcomere structure (Fig. 4  A,B) . In contrast, sarcomeres in the hearts of AKAP13-null embryos were abnormally formed with incompletely produced myofilaments that ended blindly and failed to form Z discs (Fig. 4 C,D) . Although mitosis of developing cardiomyocytes is associated with a transient de-differentiation of contractile apparatus (26) , results of Ki-67 staining did not support that explanation for the altered sarcomere structure in the AKAP13-null mice.
Loss of AKAP13 is associated with altered expression of genes involved in heart development. A failure of cardiac formation was consistent with inactivation of AKAP13, since downstream targets of Rho influence cardiomyocyte differentiation (reviewed in ref. 27) . For this reason we examined markers of cardiac development using whole-mount in situ hybridization (Fig. 5) . The results suggested expression of MEF2C was reduced in AKAP13-/-embryos. Levels of Nkx2.5 and GATA-4 transcripts (and GATA-4 protein, Suppl. Fig. 4) were not reduced in AKAP13-null embryos. Tbx2 transcripts were reduced in mutant embryos compared to wild-type littermates.
Markers were chosen to assess the Given the qualitative reduction of MEF2C in whole-mount in situ experiments, we tested whether absence of AKAP13 might be associated with a reduction in MEF2C transcripts in developing hearts at E9.0. As expected, levels of AKAP13 transcripts were reduced in heterozygous and present only at background levels AKAP13-null hearts (Fig.  6A) . Levels of MEF2C transcripts were significantly reduced (Fig. 6B) . MEF2C protein levels were also significantly reduced in cardiomyocytes derived from AKAP13-null mice compared to cardiomyocytes derived from heterozygous mice or wild-type mice (not shown).
The reduction in MEF2C led us to test whether knockdown of AKAP13 might cause a reduction in endogenous levels of transcripts encoding MEF2 or SRF (Fig. 7) . Addition of siRNA specific for AKAP-Brx resulted in an 80-90% reduction in AKAP13 transcripts (Fig.  7A, left panel) . GATA-4 transcripts were not reduced (Fig. S3 ), but transcripts of MEF2C were significantly reduced to 50% of control (Fig. 7A, middle panel) . In contrast, SRF transcripts were reduced to 30% of control following LPA stimulation (Fig. 7) . These findings indicate that AKAP13 is required for normal levels of endogenous MEF2C mRNA in heart cells, a conclusion consistent with results in Figs. 5 and 6.
Next we tested whether AKAP13 might contribute to MEF2-dependent or SRFdependent activation through Gα 12 since the contribution of Gα 12 to either SRF (28) or MEF2-dependent activation (13) had not been examined. The possible contribution of Gα 12 was of particular interest because AKAP13 has been shown to act downstream of Gα 12 in mature cardiomyocytes (29) . Transfection experiments revealed that AKAP13 caused a specific and dose-dependent increase in MEF2-dependent activation that was significantly augmented by addition of a constitutively active Gα 12 mutant (Fig. 7B) . Furthermore, activation of an SRF-dependent reporter was also enhanced, albeit to a lesser extent, in the presence of Gα 12 and was dependent upon the GEF region of AKAP13 (Fig. 7C,D) . In addition, GST-binding experiments revealed that the carboxyl region of AKAP13 bound to MEF2C, suggesting that a direct physical interaction may be involved (Fig. 8 ) that required the carboxyl region of AKAP13 (BRX). Together, the findings indicate that AKAP13 significantly enhanced MEF2-dependent gene activation through a mechanism involving Gα 12 and suggest that MEF2C activity may be dependent, at least in part, upon AKAP13 in developing cardiomyocytes.
DISCUSSION
These results reveal an essential role for AKAP13 in cardiomyocyte differentiation and heart morphogenesis. Two GEFs, Trio and Obscurin, have been implicated in control of skeletal muscle development (6), but no GEFs have formerly been reported to be essential for cardiac development. A requirement for AKAP13 in the developing myocardium is supported by recent evidence that AKAP13 influences cardiac hypertrophy through MEF2 by coupling activation of protein kinase D (PKD) with phosphorylation-dependent class II histone deacetylase HDAC5 (13). Our findings extend those observations to reveal a critical requirement for AKAP13 in the developing heart. MEF2C is the first MEF2 gene product to appear in mesodermal cells that develop into the heart (30). MEF2 proteins belong to the MADS-box family of transcriptional regulators that includes SRF. Co-transfection experiments showed that AKAP13 increased both SRF-and MEF2C-dependent reporter activity. Activation of MEF2 transcription factors leads to cardiac, smooth and skeletal muscle gene regulation (for review, 31). Of note, MEF2C-null embryos developed normally until E9.0 when a pericardial effusion developed and there was a failure of looping morphogenesis resulting in an embryonic lethal mutation (32) . Thus, the cardiac phenotype of the AKAP13-null mutant resembled the cardiac phenotype of the MEF2C-null mice.
Based on activation of AKAP13 by Gα 12 , our current working model is that splice variants of AKAP13 function in a hierarchical fashion as platforms to integrate signals emanating from cell surface receptors to transcription factors through Rho (Fig. 9 ). This interpretation is in keeping with the reported role of AKAP13 downstream of the α1 adrenergic receptor (29) , the role of AKAP13 in cardiac hypertrophy (13) , and prior studies of cardiac differentiation (see below). Two caveats are that the heart phenotype of the AKAP13 knockout could possibly be due to selective loss of MEF2 expressing cells in the heart, or a consequence of a defect in other organ systems (e.g. blood or vessels). However, evidence against an indirect etiology for the observed lethal phenotype is that AKAP13 is most heavily expressed in the heart, both during development (Fig. 2) and in adult tissues (Figs. 1E and S2) . Definitive experiments to exclude the possibility of contribution from another organ system will require a tissuespecific deletion of AKAP13 solely in the heart. It is worth noting that different-sized forms of AKAP13 appear to have distinct roles. In the heart, the larger 10kb transcript is expressed. In lymphocytes of mice the smaller 6.7kb transcript is present and regulates the response to osmotic stress (18) through activation of the nuclear factor of activated T cells 5 (NFAT5). Interestingly, several studies have shown a role for NFAT5 in endocardial cushion development in the heart (33-35).
Since AKAP13 is stimulated by Gproteins and in turn activates Rho, our transfection experiments are also supported by studies indicating an essential role of Gproteins (36) and Rho in cardiac development (37) (38) (39) . Furthermore, the AKAP13-null phenotype is supportive of previous reports indicating an important role of AKAPs in heart development (40, 41) , but our findings extend the understanding to reveal a specific developmental requirement for AKAP13.
In addition, we show by confocal microscopy and immunogold studies that AKAP13 was closely associated with actin and myosin filaments in embryonic cardiac cells. This suggests that AKAP13 functions as a scaffold protein in these cells and supports prior reports that an actin cytoskeleton was essential for RhoA-dependent activation of SRF in cardiac myocytes (37) , and that SRF was required for actin assembly (42) . Thus, it is very likely that reduced activation of SRF may contribute substantially to the observed phenotype. Our results are also supported by prior reports that AKAP13 associated with the actin-binding protein filamin (43) . It is notable that targeted deletion of filamin A (FLNA) also resulted in a severe and lethal cardiac defect (44). In support of the localization studies in Fig. 3 , a yeast two-hybrid screen using the C-terminus of Brx as bait (18) indicated that this region was capable of interaction with actin-associated proteins, including filamin A, filamin B, alpha catulin, and vimentin.
In consideration of the marked phenotype observed in AKAP13-null mice, we note that AKAP13 is the only AKAP-Rho-GEF described to date and no redundancy of the gene was apparent on our Southern analyses (ref. 1). Moreover, AKAP13 has been reported to have a 660 fold greater affinity for dephosphorylated RII (regulatory unit of protein kinase A) than AKAP 15/18 (40, 45) , suggesting that substrate affinity may explain, at least in part, the severity of the phenotype observed. More specific proof of the regions in AKAP13 required for cardiomyocyte differentiation will require a cardiac-specific conditional inactivation of this protein.
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Feng The abbreviations used are: AKAP, protein kinase A anchoring protein; Brx, Breast cancer nuclear hormone receptor auxiliary factor; GEF, guanine nucleotide exchange factor; SRF, serum response factor; MEF2C, myocyte enhancer factor-2C; LPA, lysophosphatidic acid; HDAC, histone deacetylase; NRID, nuclear receptor interacting domain; DH, Dbl-homology; PH, pleckstrin homology; RXR, retinoid X receptor; ANF, atrial naturetic factor; Cx40, connexin 40. embryos. 90-99ng of cDNA product from embryos was amplified with 33pmol of primers for either mAKAP13 (odd lanes) or GAPDH (even lanes). Murine cDNA was used as a positive control (lane 9). The expected 550bp band was present in lanes 1, 3, 7 consistent with the heterozygous genotype (black triangle). An AKAP13 transcript was not detectable in mRNA harvested from an embryo homozygous for the AKAP13 null allele (lane 5). Results were confirmed in 4 independent experiments. (E) Northern analysis of multi-tissue mRNA blot using RI-RI fragment from the 3' region of the murine AKAP13 cDNA. A 9.5-10.0 kilobase band was detected in RNA harvested from heart tissues. 9 . Model of AKAP13 action in developing heart cells. AKAP13 is activated by extracellular molecules, such as LPA (lysophosphatidic acid) through Gα 12 leading to augmentation of MEF2C and SRF activation. AKAP13 is co-localized with actin in cardiomyocytes, possibly though previously reported interactions with α−catulin (18, 28) and filamins A and B (18, 43) . MEF2C and SRF are known to play critical roles in cardiomyocyte differentiation (32, 37) 2 P.C. = postcoitum. Pregnant dams were sacrificed at days noted (column 1) and nidation sites were scored as normal (column 2), or being resorbed (column 3). Genotyping by PCR confirmed resorbing embryos were homozygous for the AKAP13-null allele, where it was possible to distinguish embryonic tissue from resorbing decidua. Gestations were scored according to the most advanced embryo development. ?others
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